Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has received production registration approvals from the National Medical Products Administration for seven pharmaceutical products, indicating a significant advancement in its product portfolio and market positioning [1]. Group 1: Product Approvals - The company has obtained approvals for the following seven drugs: 1. Arginine Perindopril Tablets (10mg), classified as a Class 4 chemical drug, is the second domestic company to receive approval, primarily used for treating hypertension and congestive heart failure [1]. 2. Progesterone Injection (II) (1.112ml: 25mg), classified as a Class 3 chemical drug, is used for progesterone supplementation in assisted reproductive technology (ART) [1]. 3. Labetalol Hydrochloride Injection (20ml: 100mg), classified as a Class 3 chemical drug, is indicated for various types of hypertension, especially hypertensive crises, and for blood pressure control before surgery [1]. 4. Calcium Chloride Injection (10ml: 1g), classified as a Class 3 chemical drug, is primarily used for treating acute hypocalcemia and magnesium poisoning [1]. 5. Compound Electrolyte Acetate Injection (500ml), classified as a Class 3 chemical drug, is used for treating isotonic dehydration with mild acidosis and for replenishing extracellular fluid and blood volume loss [1]. 6. Compound Electrolyte Injection (V) (500ml), classified as a Class 3 chemical drug, serves as a source of water and electrolytes for adults [1]. 7. Levosalbutamol Nebulization Solution (3ml: 0.63mg), classified as a Class 3 chemical drug, is used for treating or preventing bronchospasm in adults and children over 6 years old with reversible airway obstructive diseases [1].
石四药集团(02005.HK)：精氨酸培哚普利片等7个药品获药品生产注册批件